Strides Pharma Science's Q4 FY 2025-26 Quarterly Results

Result Summary

• Strides Pharma Science Ltd reported a 2.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.7%.
• Its expenses for the quarter were up by 12.0% QoQ and 10.0% YoY.
• The net profit decreased 37.9% QoQ and increased 51.0% YoY.
• The earnings per share (EPS) of Strides Pharma Science Ltd stood at 13.77 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Strides Pharma Science Ltd is a prominent player in the pharmaceutical industry, known for its focus on developing and manufacturing high-quality pharmaceutical products. The company operates in the generics segment, producing a wide array of pharmaceutical formulations across various therapeutic categories. Strides Pharma has a strong presence in key international markets, supported by robust research and development capabilities. As of the latest available information up to October 2023, the company has been actively involved in expanding its product portfolio and strengthening its market position. However, specific recent developments or strategic initiatives undertaken by the company beyond this timeframe are not available in the current context.

Revenue

During the fourth quarter of the fiscal year 2026 (Q4FY26), Strides Pharma Science Ltd reported a total income of ₹1331.60 crores. This represents a quarter-over-quarter (QoQ) increase of 2.3% compared to ₹1301.51 crores in the third quarter of the fiscal year 2026 (Q3FY26). On a year-over-year (YoY) basis, the total income increased by 10.7% from ₹1202.37 crores in the fourth quarter of the fiscal year 2025 (Q4FY25). The growth in revenue over these periods highlights the company's ability to enhance its income streams, reflecting its strategic focus on market expansion and product diversification within the pharmaceutical sector.

Profitability

Strides Pharma Science Ltd experienced fluctuations in its profitability metrics over the periods analyzed. The profit before tax (PBT) for Q4FY26 was ₹146.60 crores, marking a significant decrease of 40.3% QoQ from ₹245.51 crores in Q3FY26. Despite this QoQ decline, the YoY comparison shows a substantial increase of 42.0% from ₹103.25 crores in Q4FY25. The tax expenses for Q4FY26 were ₹18.77 crores, resulting in a profit after tax (PAT) of ₹129.28 crores, down by 37.9% QoQ from ₹208.13 crores in Q3FY26 but up by 51.0% YoY from ₹85.61 crores in Q4FY25. The earnings per share (EPS) for Q4FY26 stood at ₹13.77, reflecting a QoQ decrease of 37.2% from ₹21.92 in Q3FY26 and a YoY increase of 54.4% from ₹8.92 in Q4FY25.

Operating Metrics

The total expenses for Strides Pharma Science Ltd in Q4FY26 were ₹1178.59 crores, which is a 12.0% increase QoQ from ₹1052.70 crores in Q3FY26 and a 10.0% increase YoY from ₹1071.70 crores in Q4FY25. The increase in expenses on both a QoQ and YoY basis could be indicative of various factors including higher operational costs, research and development investments, or expansion activities. These financial metrics provide insights into the operational efficiencies and cost management strategies of the company during the analyzed period.